Logo image of ZYUS.CA

ZYUS LIFE SCIENCES CORP (ZYUS.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:ZYUS - CA9899601095 - Common Stock

0.7 CAD
0 (0%)
Last: 12/5/2025, 7:00:00 PM
Fundamental Rating

0

Overall ZYUS gets a fundamental rating of 0 out of 10. We evaluated ZYUS against 32 industry peers in the Pharmaceuticals industry. ZYUS has a bad profitability rating. Also its financial health evaluation is rather negative. ZYUS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ZYUS has reported negative net income.
In the past year ZYUS has reported a negative cash flow from operations.
In the past 5 years ZYUS reported 4 times negative net income.
In the past 5 years ZYUS always reported negative operating cash flow.
ZYUS.CA Yearly Net Income VS EBIT VS OCF VS FCFZYUS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of ZYUS (-288.90%) is worse than 93.75% of its industry peers.
Industry RankSector Rank
ROA -288.9%
ROE N/A
ROIC N/A
ROA(3y)-112.26%
ROA(5y)-68.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZYUS.CA Yearly ROA, ROE, ROICZYUS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

The Gross Margin of ZYUS (28.16%) is comparable to the rest of the industry.
ZYUS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 28.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYUS.CA Yearly Profit, Operating, Gross MarginsZYUS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K

More info and screens

0

2. Health

2.1 Basic Checks

ZYUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ZYUS has been increased compared to 1 year ago.
ZYUS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ZYUS has a worse debt to assets ratio.
ZYUS.CA Yearly Shares OutstandingZYUS.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ZYUS.CA Yearly Total Debt VS Total AssetsZYUS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -24.98, we must say that ZYUS is in the distress zone and has some risk of bankruptcy.
ZYUS has a worse Altman-Z score (-24.98) than 93.75% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -24.98
ROIC/WACCN/A
WACC7.56%
ZYUS.CA Yearly LT Debt VS Equity VS FCFZYUS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

ZYUS has a Current Ratio of 0.13. This is a bad value and indicates that ZYUS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ZYUS (0.13) is worse than 93.75% of its industry peers.
ZYUS has a Quick Ratio of 0.13. This is a bad value and indicates that ZYUS is not financially healthy enough and could expect problems in meeting its short term obligations.
ZYUS has a worse Quick ratio (0.09) than 93.75% of its industry peers.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.09
ZYUS.CA Yearly Current Assets VS Current LiabilitesZYUS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 12.65% over the past year.
The Revenue has grown by 12.85% in the past year. This is quite good.
EPS 1Y (TTM)12.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.84%
Revenue 1Y (TTM)12.85%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.69%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.34%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.77%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZYUS.CA Yearly Revenue VS EstimatesZYUS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2023 2024 2025 100K 200K 300K 400K 500K
ZYUS.CA Yearly EPS VS EstimatesZYUS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 -0.1 -0.2 -0.3 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZYUS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZYUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZYUS.CA Price Earnings VS Forward Price EarningsZYUS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYUS.CA Per share dataZYUS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ZYUS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZYUS LIFE SCIENCES CORP

TSX-V:ZYUS (12/5/2025, 7:00:00 PM)

0.7

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-27 2025-11-27
Earnings (Next)N/A N/A
Inst Owners0.17%
Inst Owner ChangeN/A
Ins Owners8.02%
Ins Owner ChangeN/A
Market Cap54.61M
Revenue(TTM)483.00K
Net Income(TTM)-34.04M
Analysts80
Price Target1.53 (118.57%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)15.84%
Min Revenue beat(2)12.87%
Max Revenue beat(2)18.81%
Revenue beat(4)3
Avg Revenue beat(4)9.59%
Min Revenue beat(4)-2.54%
Max Revenue beat(4)18.81%
Revenue beat(8)6
Avg Revenue beat(8)7.2%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 113.06
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.01
BVpS-0.13
TBVpS-0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -288.9%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 28.16%
FCFM N/A
ROA(3y)-112.26%
ROA(5y)-68.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.42%
Cap/Sales 2.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.09
Altman-Z -24.98
F-Score2
WACC7.56%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.84%
EPS Next Y18.34%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.85%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%1.69%
Revenue Next Year16.77%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-53.69%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-2659.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3028.92%
OCF growth 3YN/A
OCF growth 5YN/A

ZYUS LIFE SCIENCES CORP / ZYUS.CA FAQ

What is the fundamental rating for ZYUS stock?

ChartMill assigns a fundamental rating of 0 / 10 to ZYUS.CA.


What is the valuation status for ZYUS stock?

ChartMill assigns a valuation rating of 0 / 10 to ZYUS LIFE SCIENCES CORP (ZYUS.CA). This can be considered as Overvalued.


How profitable is ZYUS LIFE SCIENCES CORP (ZYUS.CA) stock?

ZYUS LIFE SCIENCES CORP (ZYUS.CA) has a profitability rating of 0 / 10.


What is the financial health of ZYUS LIFE SCIENCES CORP (ZYUS.CA) stock?

The financial health rating of ZYUS LIFE SCIENCES CORP (ZYUS.CA) is 0 / 10.


What is the earnings growth outlook for ZYUS LIFE SCIENCES CORP?

The Earnings per Share (EPS) of ZYUS LIFE SCIENCES CORP (ZYUS.CA) is expected to grow by 18.34% in the next year.